Quantitative ultrasound (QUS) is a non-invasive imaging modality that permits the detection of tumor response following various cancer therapies. Based on ultrasound signal scattering from the biological system, scatterer size, and concentration of microscopic scatterers, QUS enables the rapid characterization of tumor cell death. In this study, tumor response to ultrasound-stimulated microbubbles (USMB) and hyperthermia (HT) in tumor-bearing mice, with prostate cancer xenografts (PC3), was examined using QUS. Treatment conditions included 1% (v/v) Definity microbubbles stimulated at ultrasound pressures (0, 246, and 570 kPa) and HT treatment (0, 10, 40, and 50 minutes). Three ultrasound backscatter parameters, mid-band fit (MBF), 0-MHz spectral intercept (SI), and spectral slope (SS) were estimated prior to, and 24 hours after treatment. Additionally, histological assessment of tumor cell death and tissue microstructural changes was used to complement the results obtained from ultrasound data. Results demonstrated a significant increase in QUS parameters (MBF and SI) followed combined USMB and HT treatment (P<0.05). In contrast, the backscatter parameters from the control (untreated) group, and USMB only group showed minimal changes (P>0.05). Furthermore, histological data demonstrated increased cell death and prominent changes in cellular and tissue structure, nucleus size, and subcellular constituent orientation followed combined treatments. The findings suggested that QUS parameters derived from the ultrasound backscattered power spectrum may be used to detect HT treatment effects in prostate cancer tumors .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205668PMC

Publication Analysis

Top Keywords

prostate cancer
12
cell death
12
quantitative ultrasound
8
tumor response
8
tumor cell
8
data demonstrated
8
qus parameters
8
ultrasound
6
qus
5
treatment
5

Similar Publications

Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management.

Crit Rev Oncol Hematol

December 2024

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address:

In recent years, cancer immunotherapy has received widespread attention due to significant tumor clearance in some malignancies. Various immunotherapy approaches, including vaccines, immune checkpoint inhibitors, oncolytic virotherapy, bispecific T cell engagers, and adoptive T cell transfer, have completed or are undergoing clinical trials for prostate cancer. Despite immune checkpoint blockade's extraordinary effectiveness in treating a variety of cancers, targeted prostate cancer treatment using the immune system is still in its infancy.

View Article and Find Full Text PDF

A controlled study of use and effectiveness of phosphodiesterase-5 inhibitors in long-term survivors after curative radiotherapy for prostate cancer (PCa).

Radiother Oncol

December 2024

Department of Oncology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address:

Background And Purpose: We lack population-based data on the use and effectiveness of phosphodiesterase- 5inhibitors (PDE-5Is) in post-radiotherapy long-term prostate cancer survivors (PCaSs). In this cross-sectional survey performed 9 years after curative radiotherapy we explored PDE-5I use and the drugs'effectiveness in 1,092 nine-year PCaSs responding to the sexual items of EPIC-26. The findings from PCaSs were compared to those from 2,847 age-similar men from the general population (Norms).

View Article and Find Full Text PDF

Verification imaging in prostate MR-only radiotherapy: Are fiducial markers necessary?

Radiography (Lond)

December 2024

Newcastle Upon Tyne Hospitals NHS Foundation Trust, Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom; Newcastle University, Translational and Clinical Research Institute, Newcastle Upon Tyne, United Kingdom.

Purpose/objective: MR-only radiotherapy planning exploits the benefits of MRI soft-tissue delineation, whilst negating the registration inaccuracies caused by MRI CT fusion. Fiducial markers have conventionally been used in prostate radiotherapy to reduce on-treatment image matching variability. However, this is an invasive procedure for the patient, and presents technical difficulties in an MR-only pathway as fiducial markers are difficult to visualise on MRI.

View Article and Find Full Text PDF

Drug repositioning in castration-resistant prostate cancer using systems biology and computational drug design techniques.

Comput Biol Chem

December 2024

Bioinformatics Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Background And Objective: Castration-resistant prostate cancer (CRPC) is caused by resistance to androgen deprivation treatment and leads to the death of patients and there is almost no chance of survival. Therefore, finding a cure to overcome CRPC is challenging and important, but discovering a new drug is very time-consuming and expensive. To overcome these problems, we used Drug repositioning (drug repurposing) strategy in this study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!